$103 Million is the total value of CHI Advisors LLC's 13 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LVGO | New | LIVONGO HEALTH INC | $45,983,000 | – | 2,636,640 | +100.0% | 44.76% | – |
| ORTX | New | ORCHARD THERAPEUTICS PLCads | $35,524,000 | – | 2,990,211 | +100.0% | 34.58% | – |
| DTIL | New | PRECISION BIOSCIENCES INC | $9,093,000 | – | 1,083,786 | +100.0% | 8.85% | – |
| OVID | New | OVID THERAPEUTICS INC | $2,356,000 | – | 727,260 | +100.0% | 2.29% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $1,359,000 | – | 28,000 | +100.0% | 1.32% | – |
| BPMC | New | BLUEPRINT MEDICINES CORP | $1,322,000 | – | 18,000 | +100.0% | 1.29% | – |
| CRVS | New | CORVUS PHARMACEUTICALS INC | $1,175,000 | – | 390,307 | +100.0% | 1.14% | – |
| MYOK | New | MYOKARDIA INC | $1,171,000 | – | 22,464 | +100.0% | 1.14% | – |
| UMRX | New | UNUM THERAPEUTICS INC | $1,139,000 | – | 790,805 | +100.0% | 1.11% | – |
| BLUE | New | BLUEBIRD BIO INC | $1,102,000 | – | 12,000 | +100.0% | 1.07% | – |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $1,027,000 | – | 24,000 | +100.0% | 1.00% | – |
| BOLD | New | AUDENTES THERAPEUTICS INC | $983,000 | – | 35,000 | +100.0% | 0.96% | – |
| KZR | New | KEZAR LIFE SCIENCES INC | $486,000 | – | 148,092 | +100.0% | 0.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.